U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H31F3N4O4.2CH4O3S
Molecular Weight 712.755
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INCB-3284 DIMESYLATE

SMILES

CS(O)(=O)=O.CS(O)(=O)=O.COC1=NC=C(C=C1)[C@]2(O)CC[C@@H](CC2)N3CC[C@H](C3)NC(=O)CNC(=O)C4=CC(=CC=C4)C(F)(F)F

InChI

InChIKey=PNPNUHKICDECDH-FBLZNNLISA-N
InChI=1S/C26H31F3N4O4.2CH4O3S/c1-37-23-6-5-19(14-30-23)25(36)10-7-21(8-11-25)33-12-9-20(16-33)32-22(34)15-31-24(35)17-3-2-4-18(13-17)26(27,28)29;2*1-5(2,3)4/h2-6,13-14,20-21,36H,7-12,15-16H2,1H3,(H,31,35)(H,32,34);2*1H3,(H,2,3,4)/t20-,21-,25-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C26H31F3N4O4
Molecular Weight 520.5439
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

INCB3284 or INCB-3284 Incyte’s internally developed, oral human CCR2 antagonist for the treatment of chronic inflammations. It is in Phase IIa trial of patients with rheumatoid arthritis (RA).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.7 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15 h
1 times / day multiple, oral
INCB-3284 serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
58%
1 times / day multiple, oral
INCB-3284 serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed

Sample Use Guides

for once-a-day dosing
Route of Administration: Oral
Cerep screens revealed that INCB3284 is a selective CCR2 inhibitor, showing no significant inhibitory activity at a concentration of 1 μM when tested against a panel of >50 ion channels, transporters, chemokine receptors including CCR1, CCR3, CCR5, CXCR3, and CXCR5, and additional GPCRs. In the hERG patch clamp assay, INCB3284 inhibited hERG potassium current with an IC50 of 84 μM. In protein binding, INCB3284 had a high free fraction (58%) in human serum at concentrations of 1 and 10 μM. When incubated with human liver microsomes, INCB3284 exhibited a moderate intrinsic clearance. However, studies with recombinant CYP isozymes showed that INCB003284 is a substrate for CYP3A4 and CYP2D6. When INCB3284 was incubated with human S9 with or without NADPH and the cofactor glutathione, no glutathione adducts were detected. INCB003284 is not a CYP inhibitor, with IC50 values of >25 μM against five major CYP isozymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. INCB3284 is not a CYP inducer at concentrations up to 10 μM as measured in the luminometric luciferase assay.
Substance Class Chemical
Created
by admin
on Thu Jul 06 20:24:50 UTC 2023
Edited
by admin
on Thu Jul 06 20:24:50 UTC 2023
Record UNII
5ET5U3KG6K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INCB-3284 DIMESYLATE
Code English
INCB3284 BIMESYLATE
Code English
BENZAMIDE, N-(2-(((3R)-1-(TRANS-4-HYDROXY-4-(6-METHOXY-3-PYRIDINYL)CYCLOHEXYL)-3-PYRROLIDINYL)AMINO)-2-OXOETHYL)-3-(TRIFLUOROMETHYL)-, METHANESULFONATE (1:2)
Systematic Name English
INCB3284 DIMESYLATE
Code English
INCB-003284 DIMESYLATE
Code English
INCB-3284 BIMESYLATE
Code English
N-(2-(((3R)-1-(TRANS-4-HYDROXY-4-(6-METHOXY-3-PYRIDINYL)CYCLOHEXYL)-3-PYRROLIDINYL)AMINO)-2-OXOETHYL)-3-(TRIFLUOROMETHYL)-BENZAMIDE DIMETHANESULFONATE
Systematic Name English
INCB003284 DIMESYLATE
Code English
Code System Code Type Description
EPA CompTox
DTXSID20470463
Created by admin on Thu Jul 06 20:24:51 UTC 2023 , Edited by admin on Thu Jul 06 20:24:51 UTC 2023
PRIMARY
CAS
887401-93-6
Created by admin on Thu Jul 06 20:24:51 UTC 2023 , Edited by admin on Thu Jul 06 20:24:51 UTC 2023
PRIMARY
PUBCHEM
11679268
Created by admin on Thu Jul 06 20:24:51 UTC 2023 , Edited by admin on Thu Jul 06 20:24:51 UTC 2023
PRIMARY
FDA UNII
5ET5U3KG6K
Created by admin on Thu Jul 06 20:24:51 UTC 2023 , Edited by admin on Thu Jul 06 20:24:51 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY